CAPR News

Exosome Research Market Projected to Reach US$ 2,491.42 Million by 2035, Supported by Expanding Therapeutic Development Pipelines | Astute Analytica

Capriotti's Sandwich Shop Opens New Location in Phoenix on January 7

Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar Highlighting Positive Phase 3 HOPE-3 Topline Results in Duchenne Muscular Dystrophy

Capricor Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock

Capricor Therapeutics Announces Proposed Public Offering of Common Stock

Medera to Participate in Oppenheimer Movers in Rare Disease Summit 2025

Capricor Therapeutics Announces Positive Topline Results from Pivotal Phase 3 HOPE-3 Study of Deramiocel in Duchenne Muscular Dystrophy

Capricor Therapeutics Presents New Data Demonstrating a Scalable Framework for Loading Therapeutic Oligonucleotides into Exosomes at AAEV 2025

Bronstein, Gewirtz & Grossman, LLC Encourages Capricor Therapeutics, Inc. (CAPR) Shareholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Is Investigating Capricor Therapeutics, Inc. (CAPR) And Encourages Shareholders to Connect